KIT and neoplasm: Expression is therefore likely to play an important role in shaping CD8+ T cell immunodominance and CD117-blockade, potentially in combination with checkpoint inhibition, may represent a novel form of immunotherapy to increase the breadth and affinity of tumor-specific CD8+ immune responses.